PORTER, NCT03835533: Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations |
|
|
| Completed | 1 | 43 | US | NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Opdivo, Stereotactic body radiation therapy (SBRT) (Cohort B), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C), Cellectra 2000 | Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb, Celldex Therapeutics, Cancer Research Institute, New York City, Inovio Pharmaceuticals, Oncovir, Inc. | Metastatic Castration-resistant Prostate Cancer | 10/22 | 10/22 | | |
